Cohance Lifesciences Limited — Important, 12-02-2025: Financial Result Updates

Suven Pharmaceuticals has reported strong financial results for the quarter and nine months ended December 31, 2024.

**Consolidated Financials**: Revenue for Q3 reached ₹3,071.55 million, representing a robust year-over-year growth of 40%. The primary growth driver was the Pharma CDMO segment, which surged by 101% due to increased demand and successful R&D initiatives. The company's overall adjusted EBITDA margin improved to 38.7%, up from 29.1% in the previous year.

**Profit and EPS**: Net profit for the quarter is ₹1,681 million, with an adjusted PAT margin of 24.8%. The earnings per share (EPS) for the quarter stands at ₹3.39.

**Operational Costs**: Total expenses for the quarter were ₹2,620 million, a reflection of sharp improvements in operational efficiency. Notably, material costs and employee expenses were well-managed, contributing positively to the gross margin, which climbed to 71.5%.

**Balance Sheet & Cash Flow**: As of the latest reporting period, Suven maintained a healthy balance sheet with net cash of ₹137 million. Cash flow generation is strong, with free cash flow standing at ₹1.33 billion for the nine-month period.

**Strategic Position & Outlook**: Looking ahead, Suven is set to benefit from ongoing investments in R&D and expansions in its capabilities, particularly in the CDMO sector. With an expanding pipeline and strategic customer acquisitions, the company is well-positioned for sustained growth.

**Investor Insight**: Given the significant financial traction and positive outlook in key segments, it presents a favorable scenario for potential investment opportunities in the stock. A constructive view is warranted as Suven continues to build on its strategic initiatives and robust operational framework.